^
Association details:
| Biomarker: | BRCA1 mutation + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
For those with germline BRCA1/2 mutations and HR-positive, HER2-negative disease who received preoperative chemotherapy, consider adjuvant olaparib…
